CLARIFY registry designed to increase knowledge and understanding of CAD was launched in 40 countries

CLARIFY registry to improve understanding and management of heart disease

CLARIFY, the largest international registry to ever be carried out in stable coronary artery disease (CAD) patients was launched today in 40 countries, including Canada, at the European Society of Cardiology (ESC) Congress.

The CLARIFY registry (ProspeCtive observational LongitudinAl RegIstry oF patients with stable coronary arterY disease) is designed to increase knowledge and understanding of CAD and will provide important epidemiological and clinical data, including an assessment of the role of heart rate in the prognosis of CAD patients.

Coronary artery disease remains the leading cause of death worldwide. Improved understanding of the management and outcomes of these patients is paramount to reducing the disease burden. Data available today on the presentation and management of CAD stem mainly from randomised clinical trials or registries which have limited generalisability due to the stringent selection process of participants or the focus on a particular manifestation of the disease. There are only limited contemporary data regarding stable outpatients with CAD, their management and outcomes.